Expert Video - What targeted therapies are used for people with the ALK mutation?

Robert Winn, MD, director of Virginia Commonwealth University's Massey Cancer Center, identifies crizotinib and alectinib as first-line targeted therapies for people with the ALK mutation, as well as second-line therapies ceritinib and brigatinib are additional targeted therapies if the earlier treatments do not work well.

  • Share with family and friends:

Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about lung cancer which will help other patients, caregivers and families.

Other Modules:

Patient Stories: